Until the EMA meeting is over, and all parties (FDA, EMA,

New Post Public Reply Private Reply Replies (0) Message Board
Drano
282
Until the EMA meeting is over, and all parties (FDA, EMA, and IPIX) agree on the protocol, no one knows trial design.

It would be good to have different cisplatin dosages in various arms and that shouldn't be all that expensive to do that. However, the most common dosage in the future will continue to be the high dose, so that's the one that really matters. That's the dose most of the patients who need this drug will be taking.

And, as several people have pointed out, once something this convenient and easy is approved, doctors will be prescribing it off-label for people getting chemo/radiation for other cancers too. Most doctors would be much more hesitant to prescribe an IV procedure like Galera's off-label because of the expense and the risks of systemic exposure. Since Bril-OM has no systemic absorption, lots of doctors would look at it as being in the "can't hurt, might help" category and would prescribe off-label. In fact, I'd think doctors would be more worried about being sued for malpractice if a patient asked for Bril-OM and didn't get it, than they'd be worried about insurers and medical boards coming after them for prescribing it off label.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

ValidiFI Teams with Velera to Enhance Credit Union Services

Updated Category News Views 182

ValidiFI Partners with Velera to Enhance Credit Union Services ValidiFI, a recognized leader in bank account validation and payment intelligence, has joined forces with Velera, a prominent credit union service organization (CUSO). This partnership aims to provide cutting-edge financial solutions to credit unions, enhancing their member onboarding and application processes...

Continue Reading
Join the Movement: Ending Youth Homelessness This November

Updated Category News Views 168

Covenant House Urges Action: Youth Homelessness Awareness Month This November, Covenant House calls upon individuals, community advocates, business leaders, and influencers to unite and take significant actions to combat youth homelessness. As the largest nonprofit organization operating in 34 cities throughout five countries, Covenant House is dedicated to providing safe...

Continue Reading
Shilpa Pharma Lifesciences Earns EcoVadis Gold Medal for Sustainability

Updated Category News Views 142

Shilpa Pharma Lifesciences Recognized with EcoVadis Gold Medal Shilpa Pharma Lifesciences Limited has recently achieved a remarkable milestone by receiving the esteemed EcoVadis Gold Medal, awarded by the world's most recognized provider of sustainability ratings. This accolade emphasizes the dedication of the company towards sustainable practices that are vital in...

Continue Reading
Concerns for Gen Xers: Retirement Readiness Lags Behind Needs

Updated Category News Views 121

Gen X Faces Retirement Challenges As the oldest members of Generation X near the age of 60, a concerning trend is emerging regarding their financial preparedness for retirement. A recent study indicated that only a mere 14% of Americans aged 44 to 59 feel they have adequately saved for retirement. This demographic, now entering a vital stage of their lives, expresses a...

Continue Reading
Target Corporation Holiday Sales Insights and Leadership Changes

Updated Category News Views 244

Target Corporation Reports Holiday Sales Performance Target Corporation (NYSE: TGT) has announced some exciting news regarding its holiday sales performance during the combined months of November and December. The company reported a total sales increase of 2.8 percent compared to the previous year, with comparable sales increasing by 2 percent. Additionally, digital sales...

Continue Reading